图1 ASN2020荟萃分析结果
总结
越来越多的临床证据表明,沙库巴曲缬沙坦不仅仅是心衰的治疗基石,而且在CKD的全程管理中也同样具有充足的临床获益,尤其是对CKD合并心衰的患者表现出了不错的疗效,且耐受性良好,为CKD合并心衰患者的综合治疗带来了新灵感和新希望。
倪兆慧教授
参考文献:
[1] Eloise et al. PO2109 Year:2020-Renal outcomes of Sacubitril-Valsartan vs. ACE inhibitors and Angiotensin Receptor Blockers in Heart Failure: A Systematic Review and Meta-Analysis.
[2] Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2019;21(1):67-76.
[3] Haynes R, Judge PK, Staplin N, et al. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation. 2018, 138(15): 1505-1514.
[4] Uijl E, 't Hart DC, Roksnoer LCW, Groningen MCC, van Veghel R, Garrelds IM, de Vries R, van der Vlag J, Zietse R, Nijenhuis T, Joles JA, Hoorn EJ, Danser AHJ. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury. J Hypertens. 2020 Apr;38(4):755-764.
[5] Wachter R, Shah SJ, Cowie MR, Szecsödy P, Shi V, Ibram G, Zhao Z, Gong J, Klebs S, Pieske B. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Fail. 2020 Jun;7(3):856-864.
联系客服